StockData

ARS Pharmaceuticals vs Zevra Therapeutics

SPRY and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SPRY and ZVRA compare

Zevra Therapeutics is the larger company, worth 1.5 times as much as ARS Pharmaceuticals ($558M against $363M).

Zevra Therapeutics grew revenue faster over the last twelve months (119% versus 4.1% for ARS Pharmaceuticals).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −184% at ARS Pharmaceuticals.

Zevra Therapeutics scores higher on the StockData Score (15 against 8 for ARS Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSPRYZVRA
Size and price
Market cap$363M$558M
Share price$3.65$9.40
Change, 1 year−55.5%5.9%
Change, 5 years−49.2%16.8%
Beta (5Y)3.641.16
Employees15861
StockData Score
Total score815 (better)
Valuation score03 (better)
Growth score23 (better)
Performance score13 (better)
Health score56 (better)
Dividend score00
Valuation
P/E–10.1×
P/S3.1× (better)4.1×
P/B29.0×2.6× (better)
EV/EBITDA–4.0×
P/FCF–17.1×
FCF yield−54.2%5.8% (better)
Fair value–$23.57
Margin of safety–60.1%
Growth
Revenue growth (TTM)4.1%119% (better)
Revenue growth, 5Y average–51.6%
Net income growth (TTM)–2104%
Profitability
Gross margin–95.5%
Operating margin−185%60.5% (better)
Net margin−184%42.8% (better)
FCF margin−168%24.0% (better)
Return on equity−210%34.8% (better)
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.64
Interest coverage–14.4×
Current ratio3.485.17 (better)
Altman Z-score−3.094.35 (better)
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.2%78.5%
Held by insiders46.7%1.2%
Insider net buying, 12 months−$284K (better)−$2.5M
Superinvestors holding1–
Short interest, % of float35.9%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.